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ABSTRACT
Increasing amounts of systems toxicology data, including omics results, are becoming publically available and accessible in
databases. Data-driven and informatics-tool supported pipeline schemas for fitting such data into Adverse Outcome
Pathway (AOP) descriptions could potentially aid the development of nonanimal-based hazard and risk assessment
methods. We devised a 6-step workflow that integrated diverse types of toxicology data into a novel AOP scheme for
pulmonary fibrosis. Mining of literature references and diverse data sources covering previous pathway descriptions and
molecular results were coupled in a stepwise manner with informatics tools applications that enabled gene linkage and
pathway identification in molecular interaction maps. Ultimately, a network of functional elements coupled 64 pulmonary
fibrosis-associated genes into a novel, open-source AOP-linked molecular pathway, now available for commenting and
improvements in WikiPathways (WP3624). Applying in silico-based knowledge extraction and modeling, the pipeline
enabled screening and fusion of many different complex data types, including the integration of omics results. Overall, the
taken, stepwise approach should be generally useful to construct novel AOP descriptions as well as to enrich developing
AOP descriptions in progress.
Key words: Adverse Outcome Pathways; pathway analysis; pulmonary fibrosis; predictive toxicology; bioinformatics; alterna-
tives to animal testing.
Data-driven bioinformatics-based modeling is likely to capture
the dynamic nature of biological processes and serve for hy-
pothesis generation and mechanistic insight into pathobiologi-
cal effects induced by toxic agents. Pathway analysis based on
systems toxicology and omics data, and integration with pheno-
typical endpoint data, ultimately for generating toxicity predic-
tive tools, can be expected to decrease the need for animal
experiments in toxicity testing (Hartung, 2016; Thomas et al.,
2013). Helpful to this aim, diverse tools and curated molecular
pathway templates, such as WikiPathways (Kutmon et al., 2016),
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Kanehisa et al., 2017), and Reactome (Fabregat et al., 2016) per-
mit visualization and computational analysis of omics data.
Yet, the results from pathway analyses often require further
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bioinformatics analysis and expert-based interpretation
(Herwig et al., 2016). For risk assessors, the absence of estab-
lished protocols and need for expertise is an obstacle for using
omics and other systems biology data in current risk assess-
ment practice (Sturla et al., 2014).
The concept of Adverse Outcome Pathways (AOP) enables in-
corporation of mechanistic toxicity data in risk assessment
(Vinken, 2013). An AOP is a simplified schema of the central
physiological events leading to a pathological state, and uses
existing knowledge to causally connect a molecular initiating
event (MIE) to key events (KE), associative events (AE), and an
adverse outcome (AO; Vinken, 2013). The AOP-associated events
can be linked to toxicological tests and assays, which provide a
basis for integrated testing strategies predictive of adverse out-
come (Burden et al., 2015). For example, pathway analysis from
transcriptomics data have been mapped to AOP-associated
events and used as indicators of disease (Labib et al., 2015; van
der Veen et al., 2014). Additionally, the Comparative
Toxicogenomics Database (CTD) contains manually curated
multi-species information from peer-reviewed literature on
chemical/(nano)particle-gene-disease relationships reported
from a diverse array of controlled laboratory experiments
(Grondin et al., 2016). Furthermore, life science databases and
database tools such as GeneMANIA and ConsensusPathDB con-
tain information on interactions between genes and their func-
tional groupings (Kamburov et al., 2013; Warde-Farley et al.,
2010). Coupled to the recent interest of regulatory authorities to
broadly consider weight-of-evidence (WoE) data and new ap-
proach methodologies (NAMs) (ECHA, 2016), interactive and se-
quential application of such tools promises to facilitate the use
of systems toxicology data in risk assessment work.
Here, we describe and test the idea of generating an ordered,
potentially generalizable data fusion pipeline for applying di-
verse types of information and data collections for constructing
AOP-linked molecular pathway descriptions. As case study we
chose pulmonary fibrosis, a toxicology-relevant serious chronic
respiratory disease induced by a wide variety of environmental
and occupational exposures, including silica, asbestos, coal
dust, and metals (Mossman and Churg, 1998; Todd et al., 2012).
Useful to the idea of enabling a “big data and informatics tools-
driven” pipeline, the main key events underlying lung fibrosis
are well-studied, involving oxidative stress, TGF-b signaling,
disturbed extracellular matrix (ECM) production/degradation,
and inflammatory processes (Labib et al. 2015; Vietti et al., 2016).
Furthermore, studies applying nanomaterials and the genera-
tion of omics data have added dimensions to the knowledge on
the mechanisms of pulmonary fibrosis (Clippinger et al., 2016;
Dong and Ma, 2015; Dymacek et al., 2015; Poulsen et al., 2013;
Snyder-Talkington et al., 2013, 2015, 2016). On these premises,
we built a knowledge mining and informatics-dependent work-
flow for capturing existing knowledge from literature and data-
bases to a potentially risk assessment work-applicable AOP
description. Finally, we demonstrate significant outcome of the
approach from applying the substantiated AOP-description to
an independent study of nanomaterial-induced pulmonary
fibrosis.
MATERIALS ANDMETHODS
Mining of literature. Pulmonary fibrosis is a well-studied human
disease and the cumulative number of publications between
1975 and 2010 reached beyond 17 000 papers, as reviewed by
Todd et al. (2012), citing over 300 papers. We focused our search
for general schemes of pulmonary fibrosis development and
progression to recent reviews, including Todd et al. (2012), as
well as 6 other reviews (Boyles et al., 2014; Kinnula et al., 2005;
Manresa et al., 2014; Miller et al., 2014; Rockey et al., 2015;
Vancheri, 2013). In addition, 2 reviews relevant to AOP develop-
ment for pulmonary fibrosis were identified (Labib et al. 2015;
Vietti et al. 2016).
Database searching and bioinformatics processing. The widely cited
databases Comparative Toxicogenomics Database (CTD; Davis
et al., 2017), Ingenuity Pathway Analysis (IPA; Kr€amer et al.,
2014), Online Mendelian Inheritance in Man (OMIM; Amberger
et al., 2015), Causal Biological Network Database (CBN; Boue´
et al., 2015), KEGG (Kanehisa et al. 2017), and Reactome (Fabregat
et al. 2016) were found to represent pulmonary fibrosis and were
further explored for information associated with the disease.
The online interaction prediction software GeneMANIA
(Warde-Farley et al. 2010) was used to identify genetic and phys-
ical interaction links (based on curated experimentally vali-
dated interactions from the Biological General Repository for
Interaction Datasets) between pulmonary fibrosis-associated
genes selected for further development. The network was visu-
alized using Cytoscape v3.4.0 (Shannon et al. 2013), by importing
the tab-delimited GeneMANIA network file directly and apply-
ing various basic Cytoscape features, such as the circular layout
option. The interaction information was also used to define
groups of genes, eg, genes showing interactions with 1 main key
interactor were grouped together. The overrepresentation anal-
ysis tool in ConsensusPathDB (Kamburov et al. 2013) was used
to analyze for pathway enrichment among the total set of genes
selected for further analysis and for groups of genes showing
strong interactions. WikiPathways, KEGG, and Gene Ontologies
level 5 Biological Processes (with a minimum overlap of 2 genes
with the input list and p value cutoff at .01) were prioritized as
source databases, in that order. The top most significant path-
way(s) were assigned to the gene groups and used to draw con-
clusions on the genes’ involvement in molecular processes.
Pathway construction in PathVisio. PathVisio was used to draw an
interactive biological/molecular pathway in a standard GPML
format, which includes data integration (via the BridgeDb
framework; van Iersel et al., 2010) and enables use of cross data-
base identifiers, such as MIM (Molecular Interaction Maps) stan-
dard interactions, external references (eg, PubMed), and
annotations (Kutmon et al., 2015; van Iersel et al., 2008). The pul-
monary fibrosis pathway was designed by creating basic relation-
ships between the cause (oxidative stress, inflammation, and
coagulation disturbances) and effect (pulmonary fibrosis). Gene
lists of interest, selected for further development, were imported
as Human Ensembl IDs using the MAPPBuilder add-on (http://
www.pathvisio.org/plugin/mappbuilder-plugin/). Information from
the database search described earlier was then used to build con-
nections, interactions, and groupings between the different ele-
ments of the pathway (genes, pathways, and general scheme
elements) using MIM standards. In addition, where relevant, com-
putational links to corresponding pathways in the WikiPathways
and KEGG databases were generated, by using database specific
pathway identifiers. A tutorial on the technical aspects of building a
pathway can be accessed through the eNanoMapper website
(http://www.enanomapper.net/enm-tutorials) or FigShare (Ehrhart
et al., 2017).
Linkage to an AOP. A putative AOP for pulmonary fibrosis and an
associated transcriptomics data analysis (Labib et al. 2015) were
used to assign associated AOP events (MIEs, KEs, and AEs) to the
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previously identified genes and gene groups in the initial
scheme of the pathway. A description of each event (MIE, KE,
AE, and AO), as described in the original paper (Labib et al. 2015)
was also added as a legend next to the pathway itself to allow
for easy linkage to the cellular processes described for each
event.
Independent data analysis. Publically available transcriptomics
data from a study on the effects of multi-walled carbon nano-
tubes (Mitsui MWCNT-7) at 3 doses (18, 54, and 162 mg per
mouse, through intratracheal instillation) on the lungs of
C57BL/6 mice (GSE46998) was retrieved from the Gene
Expression Omnibus database (https://www.ncbi.nlm.nih.gov/
geo/). Differentially expressed genes were obtained from
Supplementary Data files in the original paper (Poulsen et al.
2013). Ensembl IDs and fold changes were imported into
PathVisio and visualized with color-codes in the mouse version
of the newly constructed pathway (WP3632).
RESULTS
Establishing aWorkflow for the Construction of an AOP-
Linked Molecular Pathway
Based on identified sources of knowledge and data, a 6-step
workflow concept for the construction of an AOP-linked molec-
ular pathway was established (Figure 1). The pipeline was tested
to build a data fusion-based pathway for pulmonary fibrosis
and the steps were applied as follows:
1. General scheme describing pulmonary fibrosis
The review by Todd et al. (2012) provided a suitable recent over-
view of pulmonary fibrosis as a basis for the pathway, listing
>300 references and providing a general scheme of the develop-
ment and progression of the disease, with linkage to the most
central molecular events. In addition, the review by Vietti et al.
(2016) was also applied to generate the initial scheme, due to its
description of alterations on molecular level related to pulmo-
nary fibrosis or fibrogenic changes. Central signaling pathways
and genes identified in the reviews included MAPK and NFKB
signaling, inflammasome activation, TNFA, IL1B, IL8 (CXCL8),
CCL2, CCL3, IL4, IL13, CTGF, IGF, TGFB1, and PDGF and SMAD
genes.
2. Assessment of databases with information on genes involved in
pulmonary fibrosis
Pulmonary fibrosis was represented by variable numbers of
genes (range: 1–99) in CBN, IPA, CTD, OMIM, KEGG, and
Reactome (February 2016; Figure 2; Supplementary Table 1).
CBN provided an unstructured network of molecules causally
associated with pulmonary fibrosis, as determined from litera-
ture, including 99 genes. IPA featured a set of 91 pulmonary
fibrosis-related genes, although without description of the un-
derlying origin of the gene connections. CTD featured 64 genes
with direct literature evidence of association (as opposed to pre-
dicted) to pulmonary fibrosis (Supplementary Table 1). In the
database access point Enrichr (Kuleshov et al. 2016; http://amp.
pharm.mssm.edu/Enrichr/), OMIM listed 12 tissue-independent
genes associated with fibrosis. KEGG provided links to other bio-
logical pathways that relate to idiopathic (unknown origin) pul-
monary fibrosis (KEGG disease pathway H01299) and listed 6
genes commonly affected by mutations in familial pulmonary
fibrosis, including references. Reactome included a pathway en-
titled “Defective SFTPA2 causes idiopathic pulmonary fibrosis
(IPF)” involving only the 1 gene—SFTPA2. None of these data-
bases provide a structured pathway or network of the genes.
CTD showed a large overlap (41%, 26/64 genes) with other
databases (Figure 2A; Supplementary Table 1), involving 12 of
the central genes and gene families as determined by the
Figure 1. The pipeline concept for constructing a bioinformatics employable
Adverse Outcome Pathway (AOP)-linked molecular pathway description based
on literature, databases, and bioinformatics-supported tools. The workflow
involves initially supervised (SV) information review followed by unsupervised
(USV) informatics-based processing and fusion of the results, and finally super-
vised association and visualization in relation to existing AOP descriptions.
Figure 2. Overlap between pulmonary fibrosis-associated genes in 6 databases;
CBN—Causal Biological Network Database, IPA—Ingenuity Pathway Analysis,
CTD—Comparative Toxicogenomics Database, OMIM—Online Mendelian
Inheritance in Man, KEGG—Kyoto Encyclopedia of Genes and Genomes, and
Reactome. A, Numbers of genes found in pairwise comparisons of the databases.
B, Sorted table with overlapping genes identified in the databases. See
Supplementary Table 1 for more details.
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literature search described earlier (Todd et al. 2012; Vietti et al.
2016). None of the other databases showed such coverage of the
literature-based genes. CTD also provided information on 53
chemicals/(nano)particles (with direct evidence) and 51 path-
ways (3 genes involved) linked to pulmonary fibrosis
(Supplementary Table 2). The top 15 (inference score>30) indi-
cations included asbestos (both serpentine and amphibole),
bleomycin, particulate matter (coal ash, dust, smog, and
smoke), lipopolysaccharides, cobalt, mustard gas, didecyldime-
thylammonium, sulfasalazine, paraquat, titanium dioxide, and
metformin. Carbon nanotubes were listed among the top 25
agents (inference score 14.68) with direct evidence of correlation
with pulmonary fibrosis. Comparing databases, the 4 most
common genes, found in 4 to 5 of the 6 databases were SFTPA2,
SFTPA1, TGFB1, and TERT (Figure 2B). Thirty-five genes were in-
dicated in 2 or more databases (Figure 2B). Due to the richness
of evidence and involvement indications, the further AOP-
enrichment effort for pulmonary fibrosis was based on adding
outstanding CTD-derived genes, ie, 52 of 64 genes without pul-
monary fibrosis/AOP association according to previous review
work.
3. Interactions between genes associated with pulmonary fibrosis
Using GeneMANIA, genetic and physical interactions were iden-
tified between 59 of the 64 CTD-derived genes (92%) (Figure 3
and Supplementary Table 3). Genes were grouped according to
Figure 3. Interaction network between 59 of the 64 CTD genes associated with pulmonary fibrosis, based on analysis in GeneMANIA. Genetic (blue online) and physical
(orange online) interactions, based on experimental evidence, are shown. The width of the edges (lines) reflects the frequency that the interaction is described in the
data sources used by GeneMANIA. White nodes correspond to the pulmonary fibrosis associated genes and gray nodes are intermediate genes added by the software
based on functional similarity (these genes were not included in the pathway). The font size of the gene name indicates the relative number of interactions with other
genes in the network (range: 1–14 interactions). Central genes identified based on literature reviews and used as focus genes for connections in the novel pathway are
indicated by red font (online). Refer to Supplementary Table 3 for details on the interactions.
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key effector genes, such as CCL2, TGFB1, PDGFB as identified
from literature, and CEBPB and SERPINA1 based on their high
numbers of interactor genes, 14 and 10, respectively
(Supplementary Table 3). The process of grouping the genes was
an interactive expert-based task applying both the gene-
interaction and pathway enrichment analyses (see below).
4. Functional schemes among the genes associated with pulmonary
fibrosis
The genes were initially grouped based on enrichment analysis
of the complete set of 64 pulmonary fibrosis associated genes,
where the most significantly enriched pathways were
“Cytokines and Inflammatory Response” (WP530; 9/64 genes; p
value 9.10E-25) and “Differentiation Pathway” (WP2848; 6/64
genes, p value 5.70E-10). The genes in both of these pathways
were grouped and computationally linked to their respective
WikiPathway IDs. In addition, groups of genes generated based
on the interactions, as described earlier, were further analyzed
separately for enriched pathways (WikiPathways and KEGG)
and Gene Ontologies (GO). The most significant pathway or in
case of no enriched pathways, GO biological process, was
assigned to the gene group.
5. Assignment of genes/gene groups to AOP-associated events for
pulmonary fibrosis
The next step in the workflow involved linkage of the genes/
gene groups independently identified in the previous steps to
a recently published putative AOP on pulmonary fibrosis
(Labib et al. 2015). Labib et al. (2015) used transcriptomics data
from nanomaterial-exposed mice that developed pulmonary
fibrosis, and correlated pathway enrichment analysis results
with MIEs, KEs, and AEs based on expert judgement. These
correlations were used in the current study to facilitate the
linking of AOP-related events to the components (genes/gene
groups associated with molecular processes/pathways) of the
pulmonary fibrosis pathway. All cellular events, ie, the MIE,
Table 1. Relationships Between AOP-Related Events, Biological Pathways Identified From Omics Data (Labib et al., 2015) and Genes/Gene
Groups (Described by Pathways) Independently Identified in the Pulmonary Fibrosis Pathway
Event Description (Labib et al.,
2015)
Labib et al., 2015 (Omics Data)a Pulmonary Fibrosis Pathwayb (WP3624) No. of Genes
Cellular
responses
MIE Cellular sensing/danger
signals
Toll-like receptor signaling Toll-like receptor signaling (WP75) 4
KE1 Induction of inflammatory
cytokines/acute phase
response
Chemokine signaling Chemokine signaling (KEGG hsa04062) 14
IL1R1-regulated signaling (IL1B,
IL6, CXCL-1, CCL2, CCL5, and
SAA3)
Cytokines and inflammatory response
(WP530)
IL1B
NFKB signaling NFKB pathway (KEGG hsa04064)
KE2 Chronic/persistant
inflammation
NFKB signaling NFKB pathway (KEGG hsa04064) –
KE3 Activation of TH2/M2 cells/in-
terleukin/growth factor
signaling
TGFB signaling TGFB1 31
TGFB signaling (WP560)
Chondrocyte differentiation (WP474)
Matrix metalloproteinases (WP129)
PDGFB
HGF signaling Differentiation pathway (WP2848)
IL-4 signaling Cytokines and inflammatory response
(WP530)
Chemokine signaling Chemokine signaling (KEGG hsa04062)
T Helper Cell Differentiation Leukocyte/Myeloid cell differentiation
(GO: 0045637/GO: 1902105)
KE4 Fibroblast/myofibroblast
proliferation
ERK/MAPK Signaling MAPK signaling (WP382) 12
p38 MAPK (WP400)
TGFB signaling TGFB signaling (WP560)
TGFB1
Chondrocyte differentiation (WP474)
Differentiation pathway (WP2848)
PDGFB
AE1 Oxidative stress NRF2-mediated Oxidative
Stress Response
NRF2 signaling (WP2884) 7
Production of Nitric Oxide and
Reactive Oxygen Species in
Macrophages
ROS production (CHEBI: 26523)
Regulation of reactive oxygen species me-
tabolism (GO: 2000377)
AE2 Cellular death Apoptosis Signaling Apoptosis (WP254) –
Organ
responses
KE5 ECM deposition Hepatic Fibrosis/Hepatic
Stellate Cell Activation
Excess deposition and/or reduced turn-
over of ECM
–
AE3 Tissue injury HIF1A signaling Collagen production –
AO Pulmonary fibrosis – Pulmonary fibrosis –
Some of the 64 genes are involved in>1 event.
aBased on canonical pathways in IPA.
bIdentified based on the 64 CTD-derived genes and independent of the original study by Labib et al. (2015).
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KEs 1–4, and AEs 1–2 could be readily mapped and associated
directly to the components of the pathway (Table 1). In addi-
tion, the tissue events KE5, AE3, and the final AO were also
assigned to general scheme elements of the pathway.
6. Integrate the data into a broad AOP-linked molecular scheme for
pulmonary fibrosis
An initial scheme of the disease was drawn in PathVisio, based
on step 1 in the workflow, and included the following events:
Lung injury and tissue response followed by inflammation, oxi-
dative stress, and coagulation disturbances leading to (1) fibro-
blast proliferation, resistance to apoptosis, differentiation into
myofibroblasts, and collagen production, (2) macrophage-
related oxidative stress and inflammasome activation, and (3)
epithelial injury and apoptosis, disturbed interaction with mes-
enchymal cells, and epithelial-mesenchymal transition (Todd
et al. 2012; Vietti et al. 2016). The effects in the 3 main cell types
together lead to excess deposition and/or reduced turnover of
ECM and consequently to pulmonary fibrosis.
Based on step 2 in the workflow, the 64 genes from CTD
were brought into PathVisio and listed beside the general
scheme. Connections between interacting genes were drawn
starting with the most central genes as assessed by the reviews,
ie, TNF, TGFB1, IL1B, SMAD7, and PDGFB (Todd et al. 2012; Vietti
et al. 2016). The connections were simplified and preferably
drawn between groups of genes defined through key interac-
tors, as described earlier in steps 3 and 4. Lines in the pathway
that reach all the way to a gene within a group indicate interac-
tion with that specific gene, whereas lines connected to a box
surrounding a group of genes indicate interaction with all or
most of the genes in the group. Genes within groups in the
pathway often also show interactions among each other, which
are not shown directly, but can be explored by clicking on the
associated pathway (the titles of the gene groups displayed in
green when exploring the pathway in PathVisio), eg, “Cytokines
and inflammatory response” (WP530). Clicking leads the user to
a pathway describing the related molecular process constructed
by other researchers in the community. Unconnected genes (as
determined by the GeneMANIA results) were listed at the top of
the scheme. The precise interactions between all genes can also
be explored in Supplementary Table 3.
At this point, the workflow had enabled generation of a
pathway that was hypothesized to encompass available, signifi-
cant information on the molecular representation of pulmonary
fibrosis. The upper elements of the pathway represent the gen-
eral scheme of pulmonary fibrosis, ie, the main cellular changes
involved in the disease progression, whereas the elements be-
low represent the underlying genes/mechanisms leading to the
final adverse outcome included at the bottom of the pathway
(Figure 4).
The next independent integration step, based on step 5 in
the workflow, included the linkage between genes and gene
groups in the pathway to AOP-related events. The relationships
between the events and omics-based pathways, described and
identified by Labib et al. (2015), and the genes/groups of genes
(related to pathways) identified in the pulmonary fibrosis path-
way are shown in Table 1 and described in detail in the
following.
MIE for Pulmonary Injury Leading to Fibrosis. In Labib et al. (2015),
the MIE is described as “cellular sensing of substance” and is
linked to pathogen associated and endocytosis signaling path-
ways, such as Toll-like receptor signaling and caveolar/clathrin-
mediated endocytosis signaling. In the pulmonary fibrosis path-
way (constructed based on steps 1–4 in the workflow), the MIE
was associated with the 4 genes, CXCL8, CCL3, CCL4, and CCL5,
which had been grouped according to their membership in the
pathway “Toll-like Receptor Signaling” in step 4 (WP75; Table 1).
Figure 4. The novel constructed bioinformatically employable AOP-linked molecular pathway (human version WP3624) describing pulmonary fibrosis. The pathway is
openly accessible at http://www.wikipathways.org/instance/WP3624.
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The MIE within the pulmonary fibrosis pathway is directly
linked with KE1 (inflammatory response), KE3 (activation of
interleukins and growth factors), and KE4 ([myo]fibroblast acti-
vation), as well as with AE2 (cellular death) demonstrating the
dynamic network with several feedback loops involved (Labib
et al. 2015).
Cellular Responses for Pulmonary Injury Leading to Fibrosis. KE 1–4.
KE1 is described as “induction of inflammatory cytokines and
acute phase response,” mainly through IL-1R1-mediated signal-
ing, involving IL1B, IL6, and CCL2 (Labib et al. 2015). In the current
pathway, KE1 is associated with IL1B, the NFKB pathway (KEGG
hsa04064), Cytokine and inflammatory response (WP530) in-
cluding the genes PDGFA, CXCL2, CSF3, CSF2, IL12B, IL13, IL4, IL5,
IL6, and Chemokine signaling (WP3929) with the genes CCL2,
CCL11, CCR2, CCR3. In total, KE1 involves 14 genes (Table 1). KE2
occurs in case of “retention or repeated exposure and/or by per-
sistent inflammation” and is also associated with the NFKB
pathway. KE2 is not represented by genes in the current path-
way, because none of the the genes chosen for constructing the
pathway (the 64 CTD genes) were directly related to NFKB sig-
naling. KE3 is described as “activation of T helper type 2 cells
and M2 macrophages, as well as interleukin and growth factor
signaling,” and was associated with PDGFB, TGFB1, TGFB signal-
ing (WP366), 3 cell differentiation pathways (the general
Differentiation pathway [WP2848], the Chondrocyte differentia-
tion [WP474—Endochondrial ossification] and Leukocyte/mye-
loid cell differentiation [GO: 0045637/GO: 1902105]), matrix
metalloproteinases (WP129) and cytokine/chemokine signaling
(WP530 and KEGG hsa04062). In total, KE3 is represented by 31
genes (Table 1). KE4 is described as “fibroblast and myofibro-
blast proliferation” and is related to MAPK signaling, growth,
and cell cycle regulation according to Labib et al. (2015), and
thus associated with 2 MAPK-related pathways (WP382 and
WP400), 2 of the differentiation pathways described earlier, as
well as PDGFB, TGFB1, and TGFB signaling. In total, KE4 is repre-
sented by 12 genes (Table 1).
AE 1–2. AE1, described as “oxidative stress” by Labib et al. (2015), is
mapped to the genes BMP7, EDN1, PLAU, PTX3, (involved in
Regulation of reactive oxygen species metabolism—GO: 2000377),
NFE2L2, HMOX1, and SERPINA1 (involved in NRF2 signaling—
WP2884; Table 1). In total, AE1 is represented by 7 genes (Table 1).
AE2, described as cellular death, is mapped to the Apoptosis path-
way (WP254), but is not represented by genes in the pathway.
Organ Responses for Pulmonary Injury Leading to Fibrosis. KE 5, AE 3,
and the AO. The organ response events AE3, KE5, and the final
AO are not directly associated with genes in the pathway, but nev-
ertheless linked to the pathway as general scheme elements. AE3,
ie, “tissue injury” as a consequence of repeated exposure and per-
sistent inflammation (KE2) leading to cytokine/growth factor sig-
naling (KE3), was linked to HIF1A signaling by Labib et al. (2015).
HIF1A signaling promotes formation of ECM through activation of
collagen genes (Gilkes et al., 2013), which led us to assign AE3 to
Collagen production (WP2798). KE5 is described as “excessive ECM
deposition and/or a reduced turnover,” due to repeated cycles of
the preceding KEs 1–4 and thus an imbalance in the metabolism
of ECM proteins, including collagen. In the new pathway, IL1B ex-
pression, involved in the initial inflammatory response (KE1), may
inhibit collagen production (AE3), as described by Todd et al.
(2012). However, collagen production might be largely mediated by
TGFB1 and TGFB signaling (involved in KE3 and 4) and the effects
of IL1B are then overruled (Todd et al. 2012). The final AO is de-
scribed as pulmonary fibrosis.
The resultant pathway has been made openly available for
use in the WikiPathways database under CC0 license (Figure 4;
WP3624). The complete history of the different construction
steps can be viewed in the database, providing transparency
and additional guidance for future building of pathways related
to other diseases/AOPs. In addition, import of data and export
of the pathway, or gene list, is possible in several formats and
can be extended by using additional plugins in, eg, PathVisio
(Kutmon et al. 2015). The pathway has also been converted into
a mouse variant (WP3632). Furthermore, in the interest of the
systems biology research on nanomaterials, the pathway has
been included in the newly established WikiPathways portal for
nanomaterial-related or -specific pathways to facilitate
community-based annotation of biological/molecular pathways
related to nanosafety (http://nanomaterials.wikipathways.org/).
Visualization of Data in the Newly Constructed Pathway
for Pulmonary Fibrosis
A transcriptomics data set representing the pulmonary effects
of MWCNT-exposure was chosen to demonstrate, in indepen-
dent data, the usefulness of the pipeline-derived novel AOP de-
scription. Fold-changes for significantly differentially expressed
genes (FDR adjusted p< .05) were obtained from the original
study; 773 for the low dose, 120 for the mid dose, and 1712 for
the high dose (Poulsen et al. 2013). PathVisio analysis of the data
using the newly constructed pathway showed, in total, differen-
tial regulation of 14 of the 64 pulmonary fibrosis-associated
genes (Figure 5). Two of four genes (50%) associate with the MIE,
3 of 7 (43%) with the AE1, 4 of 14 (29%) genes with the KE1, 5 of
31 (16%) genes relate to KE3, and 1 of 12 genes (8%) relate to KE4.
Based on the pipeline starting point, ie, the reviews by Todd
et al. (2012) and Vietti et al. (2016), 11 of overall 14 genes would
have gone undetected as pulmonary fibrosis AOP-associated,
including CCL5, CCL11, and IL6, which have been found at in-
creased levels in bronchioalveolar lavage samples from pulmo-
nary fibrosis patients (Emad and Emad, 2007a,b).
DISCUSSION
A pipeline to generate AOP-linked molecular pathway descrip-
tions in support of WoE biological data and NAMs was devel-
oped under a 6-step protocol (cf. Figure 1). The workflow is both
data-driven and informatics- and visualization-tools depen-
dent, involving initially supervised information review fol-
lowed subsequently by unsupervised informatics-based
processing and fusion of the combined results into molecular
interaction networks. The networks were then in turn assigned
and plotted relating to earlier AOP descriptions for pulmonary
fibrosis, leading ultimately to a further substantiated AOP de-
scription. Assessment in independent data indicated that the
approach successfully had enriched the AOP description with
MIE and KE-related molecular data. Relevant expertise is natu-
rally a key dimension to the work process, yet the tools, and
the suggested order of applying the tools generate a structured
means of combining supervised and unsupervised data man-
agement (cf. Figure 1). We consider the composite pipeline
concept therefore to have strong potential to aid the many
AOP descriptions that are known for being in current develop-
ment phase.
The pathways and AOP descriptions generated from follow-
ing the workflow are currently openly available for inspection
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and input, with interactive schemes useful for both intuitive vi-
sualization and computational analysis of diverse omics data.
The pathways are applicable as multivariate biomarkers for hy-
pothesizing and/or predicting the final adverse outcomes re-
lated to specific exposures. They allow a user to dig deeper into
the underlying mechanisms through links with associated
knowledge (genes/pathways) and thus, provides transparency
with regard to the information that they build upon. The linked
data in such pathways enable structured computational analy-
ses useful for integration of diverse data, which is common
within the multidisciplinary field of toxicology and particularly
within risk assessment. Linked data also allow for informed se-
mantic querying in databases, eg, in this case for looking up
agents that activate certain genes or pathways (Jeliazkova et al.
2015). This is particularly useful when coupled to a structured
harmonized terminology, ie, an ontology. An AOP-specific on-
tology has recently been described and provides a basis for fu-
ture AOP-linked database searches (Burgoon, 2017). Overall, we
see the open source approach to the pipeline concept being piv-
otal to future AOP developments, as further data and knowledge
thereby becomes easily incorporated under the existing proto-
col and overall stepwise construction approach.
The pipeline concept was successfully used to generate an
AOP-linked molecular pathway description of the occupationally
relevant disease pulmonary fibrosis. The resultant pathway
model deepens the understanding of involvement of genes and
molecular mechanisms underlying the disease by revealing how
64 pulmonary fibrosis associated genes are interlinked, which
functions and existing pathways the genes relate to, and, more
importantly, which of the AOP-associated events that are poten-
tially critical (cf. Figure 4). In this case, the genes were derived
from CTD, which provided a firm connection between the genes
and the disease (including literature references), as well as to
agents associated with the disease. The molecular pathway de-
scription was built primarily based on the 64 genes and the anal-
yses of their interactions and functional associations (cf. Figure
1, steps 2–4). Nevertheless, interestingly, all AOP-associated
events in the previously described putative AOP for the disease,
from the MIE to the AO (Labib et al. 2015), corresponded well and
could be readily linked to the established components (genes/
gene groups) of the pathway (cf. Figure 1, step 5).
The pulmonary fibrosis pathway was constructed to repre-
sent a dynamic network, in contrast to the higher level linear di-
rected flow of processes or interactions typical for an AOP. For
example, some of the AOP-related events are represented by
the same genes or gene groups, eg, KE1 and KE3 both relate to
cytokine and chemokine signaling, largely due to the dynamic
nature of pulmonary fibrosis, which progresses through cycles
Figure 5. Visualization of a transcriptomics data set, representing the effects of MWCNT exposure (at 3 doses) on the lungs after 1 day, in the AOP-linked molecular
pathway for pulmonary fibrosis (mouse version WP3632). Red and green (online) indicates up- and down-regulation, respectively, and the regulation can be seen for
each dose separately, as indicated by the diagram at the upper right corner (A). Deregulation of all represented AOP-related events can be seen, including the MIE, AE1,
KE1, KE3, and KE4 (B). Crossed boxes indicate associated pathways, which can be explored in relation to the analyzed data by clicking (in PathVisio).
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of repeated tissue injury and persistent inflammation (Labib
et al. 2015). In addition, autocrine control of growth factors adds
to these feedback loops and thus, KE3 and KE4 were also repre-
sented by overlapping sets of genes involved in differentiation
pathways. Future evidence may specify the order and associa-
tion of certain molecular pathways with specific AOP-related
events. On the other hand, some of the AOP-related cellular
events were not linked to any genes in the pathway, ie, KE2 and
AE2. This may indicate areas (or events) in need of further re-
search to pinpoint the underlying molecular patterns. Such
efforts would strengthen the direct evidence of association in
databases such as CTD, giving reason for incorporation of fur-
ther key genes in the pathway. Finally, AE3, KE5, and the final
AO are described as tissue or organ level responses, and al-
though they are not currently represented by associated genes
in the new pathway, they are included at the bottom to enable
future computational linkage. Future linkage to, eg, collagen
genes with AE3 or KE5 can be foreseen.
The independent data analyzed to visualize applicability of
the pipeline concept included transcriptomics data from
MWCNT-exposed mice, which rapidly develop pulmonary fibro-
sis (Porter et al., 2010; Poulsen et al. 2013). The overall analysis
implicated deregulation of all AOP-related events represented
by genes in the pathway, ie, the MIE, AE1, KE1, KE3, and KE4.
Interestingly, these genes were indicated already 1-day post-
exposure (cf. Figure 5), although evident fibrotic changes as
detected by histopathological analysis were seen much later (7-
day post-exposure; Porter et al. 2010). Furthermore, a strong
involvement of genes associated with the early events, ie, the
MIE (50% of genes deregulated), the AE1 (43%), and the KE1
(29%), and less involvement of the later events KE3 (16%) and
KE4 (8%) could be observed. Although the low number of altered
genes prevents statistical analysis, these results may reflect the
early time point, where the MIE can be assumed to be the most
strongly affected, whereas KE4 is just about to kick in (Figure 6).
The fact that also AE1 was so strongly affected (43%) already at
this point, indicated its potentially strong involvement in the
initiating event and progress toward the next KEs (Figure 6).
Finally, the new AOP description enabled identification of 11
pulmonary fibrosis AOP-related genes which would not have
been identified based on the previous descriptions of the dis-
ease (Todd et al. 2012; Vietti et al. 2016). Overall, this indepen-
dent analysis supported that transcriptomics data captures
early effects of the exposure, and in particular before the AO
becomes histologically detectable.
The pulmonary fibrosis pathway serves as a detailed exam-
ple for the generation of AOP-linked molecular pathways for
other diseases. Fibrosis can occur in most organs and involves
largely similar molecular responses (Rockey et al. 2015).
Therefore, besides the generalizability of the proposed work-
flow, the knowledge gained in this case study could be used as a
basis for the development of similar pathways descriptive of fi-
brosis in other organs, eg, liver fibrosis, currently described as
an established (OECD reviewed) AOP (https://aopwiki.org/aops/
38). Recent thinking on novel ways of toxicity testing argues for
the application of omics data and AOP-linked molecular path-
ways (Kohonen et al. 2017). A number of current initiatives are
strongly focused on the development and use of high-
throughput data generation and omics methodology (Collins
et al., 2017; Merrick et al., 2015). Such data are directly applicable
to AOP-targeted pathway analyses, including, (1) disease-linked
overrepresentation analysis, (2) disease-linked enrichment
analysis among differentially expressed genes, (3) integration
into AOP-based testing strategies as multivariate biomarkers
(Tollefsen et al., 2014), (4) application as disease-linked descrip-
tors in (quantitative) structure-activity relationships ((Q)SAR)
approaches (Tsiliki et al. 2017), and finally, based on all the
above, enable (5) disease-linked grouping and read across
among toxic agents through implementation into omics-based
toxicity predictive tools. In relation to this, our laboratory re-
cently described a Predictive Toxicogenomics Space (PTGS) scor-
ing concept that gives any omics analysis a predictive toxicity
effect (Kohonen et al., 2017). Such analyses could be part of
tiered workflows involving, in addition to omics modeling,
high-throughput screening for ranking and prioritizing, and
high-content analysis for validation of the omics-based AOP-
linked hypotheses (Grafstro¨m et al., 2015). Thus, although the
pipeline-derived AOP descriptions are currently primarily quali-
tative, future directions will operate to incorporate increasingly
quantitative approaches (Grafstro¨m et al. 2015; Kohonen et al.
2017).
The suggested AOP-enriching approach is likely applicable
from different angles depending on the data available for the
specific disease under investigation. The case study chosen to
test the approach was based on genes identified from CTD, and
although the database is one of the most comprehensive gene-
disease relationship sources, future efforts may refine the iden-
tification of key disease-related genes to be based on multiple
sources of information. Furthermore, validation, especially
from a regulatory point of view, will require large-scale data
sets covering at least 30–50 compounds or nanomaterials per
AOP, and preferably hundreds, for sufficient statistical power to
Figure 6. Differentially expressed genes in MWCNT-exposed mice 1-day post-
exposure show strong involvement in early pulmonary-fibrosis related events
(MIE, AE1, and KE1), with decreases in later events (KE3 and 4).
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test sensitivity, specificity, and coverage (ie, application do-
main). In addition, these data should preferably cover broad
dose ranges, although tiered testing strategies in conjunction
with high-content screening data may be able to reduce that
need (Grafstro¨m et al. 2015). The required large-scale and mainly
in vitro-based gene expression data sets can be expected to be
generated as part of future efforts that utilize high-throughput
transcriptomics technologies similar to the TempO-seq Tox21
Phase III L1500þ or the Broad Institute Connectivity Map L1000
platform (Andersen et al. 2015; Collins et al. 2017; Subramanian
et al. 2017). Ultimately, transcriptomic benchmark dose-re-
sponse analyses may utilize WikiPathways resources such as
this one, the PTGS or other high-quality targeted gene set collec-
tions as part of a validated scoring concept workflow tailored to
each AOP (Dean et al. 2017; Kohonen et al. 2017).
In summary, we present an open source, diverse data, and
bioinformatics tool-dependent pipeline concept that lies at the
heart of accepting WoE, NAMs, and AOP-linkage for risk charac-
terization work. Taking pulmonary fibrosis as case study, the
analysis pointed to both known and novel gene associations, al-
though it served primarily to demonstrate the functionality of
using a mixed supervised versus unsupervised but fixed proto-
col for developing AOP descriptions. We believe such an ap-
proach to be gaining momentum within risk assessment
practices, and in fact the generalized pipeline described here,
might be suitable for standardized use to generate descriptions
of further toxicity-relevant diseases. Molecular pathways linked
to AOPs provide clarity in the complexity of biology, and provide
a much-needed basis for decisions on further testing and vali-
dation needs of central events. With the implementation of
novel AOP methodology such as that described herein, future
cost-effective early phase routine safety testing practices will
increasingly ensure that chemicals and engineered nanomateri-
als are generated and applied under a safe innovation
approach.
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